BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability (2020)

BridgeBio Pharma's (BBIO) quarterly Non-Current Deferred Tax Liability came in at $1.1 million in Q4 2020.

BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability (2020) Analysis & Trends

BridgeBio Pharma has disclosed Non-Current Deferred Tax Liability across 1 years of filings, most recently posting $1.1 million for Q4 2020.

Non-Current Deferred Tax Liability for Q4 2020 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $1.1 million (changed N/A YoY), and the FY2020 annual result was $1.1 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability came in at $1.1 million for Q4 2020 at BridgeBio Pharma.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2020 to a low of $1.1 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	BridgeBio Pharma	12.90 Bn	11.97 Bn	184.58 Mn

Download Data

Date	Value
Dec 31, 2020	1.10 Mn
Dec 31, 2020	1.10 Mn